PRAXIS BIOLOGICS AND CYANAMID WILL CONJUGATE IN DEAL WORTH OVER $ 200 MIL.; VACCINE FIRM'S CORE ANTIGEN TECHNOLOGY COMPLEMENTS LEDERLE PIPELINE